UNSPSC 51433924: Amlodipine besilate

This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 864V2Q084H, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester but more generally known as amlodipine besilate, which bears US NIH Compound Identifier 2162.

European Medicines Agency schedules Amlodipine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12864MIG. Most nations, for tariff and trade purposes, schedule amlodipine besilate under HS 29333999 and SITC 51574. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2CL)C(=O)OC)C)COCCN.C1CCC(CC1)S(=O)(=O)O.

UNSPSC 51433924 Amlodipine besilate is a Commodity code covering a single active pharmaceutical ingredient used primarily in cardiovascular emergency response and chronic hypertension management. State and local governments procure this medication through emergency medical services departments, fire rescue agencies, and healthcare benefit programs that distribute it to hospitals, clinics, and emergency response teams. The code encompasses amlodipine besilate in finished pharmaceutical form—typically as vials or tablets ready for clinical use—supplied by manufacturers and wholesalers under firm pricing agreements that include expiration-date warranties, temperature control during transit, and replacement obligations for degraded stock. Issuing bodies span city fire departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The City of Tampa and MMCAP appear as active repeat buyers in recent activity, with Tampa managing direct city-level procurement and MMCAP coordinating supply across multiple state and local member jurisdictions.

Recent procurement activity centers on three distinct sourcing models. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026, estimated contract value $40,000) bundling amlodipine besilate and related emergency cardiac medications for Tampa Fire Rescue; the solicitation required nine-month minimum shelf life, firm pricing including freight to Tampa, Florida, and SLBE sheltered-market participation with a 5 percent bid discount. MMCAP posted RFP S1070000015802 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), provide NDC-level pricing in multiple formats (flat, net, WAC-minus), and comply with cGMP and Drug Supply Chain Security Act standards; the contract term runs two years with optional extensions through June 30, 2028. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer pharmacy initiative, signaling future formal procurement but not yet a binding opportunity. Geographic activity spans Florida, Texas, and Minnesota–Oregon, with cooperative purchasing models expanding reach across multiple jurisdictions.